An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study

• Published in: Journal of translational medicine Vol. 22; no. 1; p. 366
• Main Authors: Cheng, Yifei, Wu, Lang, Xin, Junyi, Ben, Shuai, Chen, Silu, Li, Huiqin, Zhao, Lingyan, Wang, Meilin, Cheng, Gong, Du, Mulong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.04.2024; BioMed Central; BMC
• Subjects: Age-specific genome-wide association studies; Analysis; Care and treatment; Cohort Studies; Diagnosis; Early-onset prostate cancer; Genetic aspects; Genetic Predisposition to Disease; Genetic Risk Score; Genome-wide association studies; Genome-Wide Association Study; Health risk assessment; Humans; Male; Methods; Phenome-wide association studies; Polygenic risk score; Prostate cancer; Prostatic Neoplasms; Risk Factors; UK biobank; United Kingdom; Polygenic risk score; Early-onset prostate cancer; Age-specific genome-wide association studies; Phenome-wide association studies; UK biobank
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-05190-y

Early-onset prostate cancer (EOPC, ≤ 55 years) has a unique clinical entity harboring high genetic risk, but the majority of EOPC patients still substantial opportunity to be early-detected thus suffering an unfavorable prognosis. A refined understanding of age-based polygenic risk score (PRS) for prostate cancer (PCa) would be essential for personalized risk stratification. We included 167,517 male participants [4882 cases including 205 EOPC and 4677 late-onset PCa (LOPC)] from UK Biobank. A General-, an EOPC- and an LOPC-PRS were derived from age-specific genome-wide association studies. Weighted Cox proportional hazard models were applied to estimate the risk of PCa associated with PRSs. The discriminatory capability of PRSs were validated using time-dependent receiver operating characteristic (ROC) curves with additional 4238 males from PLCO and TCGA. Phenome-wide association studies underlying Mendelian Randomization were conducted to discover EOPC linking phenotypes. The 269-PRS calculated via well-established risk variants was more strongly associated with risk of EOPC [hazard ratio (HR) = 2.35, 95% confidence interval (CI) 1.99-2.78] than LOPC (HR = 1.95, 95% CI 1.89-2.01; I  = 79%). EOPC-PRS was dramatically related to EOPC risk (HR = 4.70, 95% CI 3.98-5.54) but not to LOPC (HR = 0.98, 95% CI 0.96-1.01), while LOPC-PRS had similar risk estimates for EOPC and LOPC (I  = 0%). Particularly, EOPC-PRS performed optimal discriminatory capability for EOPC (area under the ROC = 0.613). Among the phenomic factors to PCa deposited in the platform of ProAP (Prostate cancer Age-based PheWAS; https://mulongdu.shinyapps.io/proap ), EOPC was preferentially associated with PCa family history while LOPC was prone to environmental and lifestyles exposures. This study comprehensively profiled the distinct genetic and phenotypic architecture of EOPC. The EOPC-PRS may optimize risk estimate of PCa in young males, particularly those without family history, thus providing guidance for precision population stratification.